These results demonstrate that p53 activation by MDM2 blockade can sensitize BC CML cells, including quiescent CD34+ cells, to Bcl-2 inhibitor- and TKI-induced apoptosis. Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.